JAC-Antimicrobial Resistance最新文献

{"title":"Comparative <i>in vitro</i> activity of sulbactam with avibactam or durlobactam against carbapenem-resistant <i>Acinetobacter baumannii</i>.","authors":"Ava J Dorazio, Ellen G Kline, Kevin M Squires, Marissa P Griffith, Yohei Doi, Ryan K Shields","doi":"10.1093/jacamr/dlaf098","DOIUrl":"10.1093/jacamr/dlaf098","url":null,"abstract":"<p><strong>Objective: </strong>To determine the <i>in vitro</i> activity of sulbactam in combination with avibactam or durlobactam with and without meropenem or imipenem against carbapenem-resistant <i>Acinetobacter baumannii</i> clinical isolates.</p><p><strong>Methods: </strong>Standardized susceptibility testing by broth microdilution was performed to determine MICs for imipenem, meropenem and sulbactam alone, and for combinations including sulbactam/avibactam, sulbactam/durlobactam, sulbactam/avibactam/meropenem, sulbactam/avibactam/imipenem, sulbactam/durlobactacm/meropenem and sulbactam/durlobactam/imipenem. Whole-genome sequencing was also performed to compare MICs to key resistance determinants, including mutations in penicillin-binding proteins (PBPs).</p><p><strong>Results: </strong>Median sulbactam/durlobactam and sulbactam/avibactam MICs were 2 and 16 mg/L, respectively. Imipenem potentiated the <i>in vitro</i> activity of both combinations to a greater extent than meropenem corresponding to median sulbactam/durlobactam/imipenem and sulbactam/avibactam/imipenem MICs of 1 and 8 mg/L, respectively. Carbapenem combinations were more active than combinations without a carbapenem against isolates with PBP3 mutations.</p><p><strong>Conclusions: </strong>These data show that imipenem potentiates sulbactam-based combinations to a greater extent than meropenem; however, future studies are needed to define how these data should be applied in clinical practice.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf098"},"PeriodicalIF":3.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.","authors":"Ana Alarcia-Lacalle, Andrés Canut-Blasco, María Ángeles Solinís, Arantxa Isla, Alicia Rodríguez-Gascón","doi":"10.1093/jacamr/dlaf096","DOIUrl":"10.1093/jacamr/dlaf096","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial resistance is a global public health threat that requires urgent solutions. One strategy to decrease resistance of Gram-negative bacteria (GNB) to β-lactam antibiotics (BL) is their combination with β-lactamase inhibitors (BLI).</p><p><strong>Objectives: </strong>This systematic review analyses the outcomes, safety and pharmacokinetics (PK) of recently approved or under clinical development BLI and BL/BLI combinations.</p><p><strong>Methods: </strong>The systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. PubMed, Embase, and Cochrane electronic databases were used to search for articles from January 2010 to November 2024. The studies were retrieved and screened on the basis of predefined exclusion and inclusion criteria. A quality assessment of the included studies was conducted following the New Castle-Ottawa Scale.</p><p><strong>Results: </strong>A total of 191 articles addressing clinical research regarding the efficacy, safety, tolerability, and PK of new BL/BLI combinations with avibactam, durlobactam, enmetazobactam, nacubactam, relebactam, taniborbactam, tazobactam, vaborbactam and zidebactam were included. According to the published literature, clinical research supports the novel BL/BLI combinations for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired and ventilator-associated pneumonia (HAP/VAP) caused by GNB. In spite of that, the development of new BLI effective for class B metallo-β-lactamases (MBL) is still challenging, being aztreonam/avibactam the only approved combination active against MBL-producing bacteria.</p><p><strong>Conclusions: </strong>Although there has been extensive research to develop new BLI and BL/BLI combinations, only a few have reached the market. More evidence of its usefulness in the real world is still needed.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf096"},"PeriodicalIF":3.7,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Over-the-counter antimicrobial dispensing in Lusaka Province retail pharmacies, Zambia.","authors":"Kelly Chisanga, Ernest Simpemba, Chipwaila Chunga, Victor Chalwe, Otridah Kapona, Winfredah Nyirenda, James Mwansa, Godfrey Biemba","doi":"10.1093/jacamr/dlaf092","DOIUrl":"10.1093/jacamr/dlaf092","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial resistance (AMR) is a major global threat, projected to cause 10 million deaths annually by 2050, mostly in sub-Saharan Africa. Indiscriminate dispensing and policy non-adherence worsen AMR, yet non-prescription antimicrobial use persists. This study examines over-the-counter (OTC) antimicrobial dispensing by pharmacy personnel in Lusaka Province, Zambia.</p><p><strong>Objective: </strong>To describe OTC antimicrobial dispensing by retail pharmacy personnel in Lusaka Province and its implications for AMR.</p><p><strong>Methods: </strong>We conducted a cross-sectional survey using simulated clients at 142 retail pharmacies to assess OTC antimicrobial dispensing practices.</p><p><strong>Results: </strong>Of the 142 retail pharmacies in Lusaka visited by simulation clients seeking antimicrobials without prescriptions, 90.1% complied with the requests. While 28.9% mentioned that a prescription was needed, only 25.4% advised clients to obtain one. Additionally, 83.3% recommended buying antimicrobials instead of visiting a hospital, with in-pharmacy treatment rates of 86.7% for Upper Respiratory Tract Infection symptoms, 90.5% for cough and 91.7% for sore throat.</p><p><strong>Conclusions: </strong>We observed a high level of OTC antimicrobial dispensing among retail pharmacy personnel in Lusaka Province, which may hinder efforts to combat AMR in Zambia. Although the study lacked qualitative data to explore the reasons behind this practice, such research is urgently needed. Nonetheless, our findings highlight the need for the ZMRA to enhance monitoring of retail pharmacies to ensure adherence to international antimicrobial dispensing standards and help reduce AMR.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf092"},"PeriodicalIF":3.7,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of ceftazidime/avibactam in combination with colistin against KPC-2-producing <i>Klebsiella pneumoniae</i> in static and dynamic time-kill experiments.","authors":"Lisa Allander, Emma Vikdahl, Margarita Chatzopoulou, Amaury O'Jeanson, Linus Sandegren, Pernilla Lagerbäck, Thomas Tängdén","doi":"10.1093/jacamr/dlaf105","DOIUrl":"10.1093/jacamr/dlaf105","url":null,"abstract":"<p><strong>Objectives: </strong>Ceftazidime/avibactam is used for severe infections caused by carbapenemase-producing <i>Klebsiella pneumoniae</i>. Combination therapy with older antibiotics is frequently used, but the supporting data are limited. This study aimed to evaluate ceftazidime/avibactam in combination with colistin against KPC-2-producing <i>K. pneumoniae</i>.</p><p><strong>Material and methods: </strong>Five clinical KPC-2-producing <i>K. pneumoniae</i> strains were characterized by phenotypic antibiotic susceptibility testing and whole-genome sequencing. Single antibiotics and combinations were evaluated in 24-h static time-kill experiments with ceftazidime/avibactam concentrations of 0.5× MIC_ratio and colistin at 0.5× and 1× MIC. One strain was subjected to 32-h dynamic time-kill experiments with ceftazidime/avibactam at concentrations mimicking patient pharmacokinetics in plasma and colistin added to 1 mg/L, i.e. the average free steady-state concentration. Population analysis was performed at 0, 16, and 32 h by plating at 4× and 8× MIC_ratio (ceftazidime/avibactam) or MIC (colistin) to assess resistance development.</p><p><strong>Results: </strong>All strains were susceptible to ceftazidime/avibactam and colistin, had mutations in <i>ompK35</i> and <i>ompK36</i>, and carried multiple β-lactamase genes. Ceftazidime/avibactam combined with colistin demonstrated 24-h synergy in static time-kill experiments against 3 of 5 strains. Although ceftazidime/avibactam and colistin alone showed rapid initial killing in the dynamic experiments, regrowth occurred after 4-8 h. The three-drug combination displayed a bactericidal effect and synergy at 14-32 h. Resistance development resulting in 64-fold MIC increases was observed in experiments with colistin alone.</p><p><strong>Conclusions: </strong>This study showed synergy with ceftazidime/avibactam and colistin against KPC-2-producing <i>K. pneumoniae</i> at clinically relevant concentrations. More studies are warranted to investigate the clinical potential of this combination.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf105"},"PeriodicalIF":3.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12203663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Escherichia coli</i> producing AmpC DHA-1 bacteraemia in neutropenic leukemic patient: continuous infusion ceftazidime/avibactam as a carbapenem sparing regimen.","authors":"S Giuliano, A Piccirilli, J Angelini, F Patriarca, R Fanin, L Martini, T Semenzin, M Fanin, S Lanini, R A Bonomo, M Perilli, C Tascini","doi":"10.1093/jacamr/dlaf109","DOIUrl":"10.1093/jacamr/dlaf109","url":null,"abstract":"<p><strong>Background: </strong><i>Escherichia coli</i> resistant to third-generation cephalosporins, primarily due to the production of ESBLs and AmpC β-lactamases, poses a significant therapeutic challenge, particularly in immunocompromised patients. Ceftazidime/avibactam (CZA) has emerged as a potential carbapenem-sparing option, though data on its efficacy against AmpC-producing Enterobacterales remain limited.</p><p><strong>Methods: </strong>We report a case of bloodstream infection (BSI) caused by an <i>E. coli</i> strain harbouring the plasmid-mediated AmpC enzyme DHA-1 in a neutropenic patient following allogeneic haematopoietic stem cell transplantation. The strain was characterized via whole-genome sequencing and conjugation assays. Therapeutic drug monitoring (TDM) was used to guide a continuous infusion CZA regimen in the context of augmented renal clearance (ARC).</p><p><strong>Results: </strong>The patient responded favourably to CZA therapy (2.5 g every 8 h via continuous infusion for 9 days), with rapid microbiological clearance and clinical improvement. TDM confirmed therapeutic plasma concentrations of both ceftazidime (29.57 mg/L) and avibactam (5.52 mg/L). Genomic analysis revealed multiple resistance genes (<i>blaDHA-1</i>, <i>qnrB4</i>, <i>mphA</i>, <i>dfrA7</i>) and virulence factors, with the isolate identified as <i>E. coli</i> ST442, serotype O174:H9. The early switch from meropenem to CZA may have contributed to microbiota preservation and prevented subsequent infection by carbapenemase-producing <i>Klebsiella pneumoniae</i>, for which the patient was colonized.</p><p><strong>Conclusions: </strong>This case illustrates the clinical utility of a carbapenem-sparing strategy guided by TDM in a high-risk, ARC patient with an AmpC-producing <i>E. coli</i> BSI. Continuous infusion CZA achieved pharmacokinetic/pharmacodynamic targets associated with therapeutic success, offering a promising alternative to carbapenems while mitigating the risk of resistance development and microbiota disruption.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf109"},"PeriodicalIF":3.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12203789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eravacycline as a last resort for difficult-to-treat resistant <i>Acinetobacter baumannii</i> infections in critically ill patients: three case reports with pharmacokinetic insights.","authors":"Leo Mimram, Jean-François Timsit, Emilie Rondinaud, Minh Le, Michael Thy","doi":"10.1093/jacamr/dlaf095","DOIUrl":"10.1093/jacamr/dlaf095","url":null,"abstract":"<p><strong>Objectives: </strong>To describe eravacycline use as a salvage treatment for ventilator-associated pneumonia (VAP) caused by difficult-to-treat resistant (DTR) <i>Acinetobacter baumannii</i> in critically ill patients.</p><p><strong>Methods: </strong>We reported three cases of DTR <i>A. baumannii</i> VAP with multiple organ failure treated with eravacycline. Patients were critically ill with confirmed VAP by distal pulmonary cultures. Eravacycline was administered at 1 mg/kg q12h in combination with IV colistin or as primary therapy. Clinical and microbiological outcomes were assessed.</p><p><strong>Results: </strong>Eravacycline MICs ranged from 0.25 to 0.75 mg/L. Microbiological success was observed in the three cases, including one patient who was successfully weaned and discharged alive with no further samples submitted for microbiological culture, and two other patients who were repeatedly sampled and remained negative for <i>A. baumannii</i>. Clinical success could not be confirmed in one case. No adverse effects were observed. Pharmacokinetic analysis of concentrations from a single patient revealed a maximal concentration (<i>C</i> _max) of 1.47 mg/L at 1 h and an AUC_0-6 of 2.88 mg·h/L. The epithelial lining fluid/plasma concentration ratio was 0.1.</p><p><strong>Conclusions: </strong>Eravacycline showed promise as a salvage therapy for DTR <i>A. baumannii</i> VAP in critically ill patients. Further studies are needed to confirm its efficacy and optimal dosing in this setting.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf095"},"PeriodicalIF":3.7,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12203001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination therapy with fosfomycin for <i>Staphylococcus aureus</i> bacteraemia or endocarditis: a systematic review and meta-analysis of randomized trials.","authors":"Ahmad Mourad, Joshua B Parsons, Lesley A Skalla, Thomas L Holland, Timothy C Jenkins","doi":"10.1093/jacamr/dlaf101","DOIUrl":"10.1093/jacamr/dlaf101","url":null,"abstract":"<p><strong>Background and objectives: </strong>Fosfomycin combination therapy for <i>Staphylococcus aureus</i> bacteraemia or endocarditis has been evaluated, but studies were limited by small sample sizes. We sought to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) to establish robust efficacy and safety estimates of fosfomycin combination therapy in this patient population.</p><p><strong>Data sources: </strong>MEDLINE, Embase, Cochrane Library and Web of Science databases were searched from inception through September 2024 (PROSPERO CRD42024583822).</p><p><strong>Study eligibility: </strong>RCTs comparing fosfomycin combination with standard-of-care antibiotics in patients with <i>S. aureus</i> bacteraemia or endocarditis were included. Two independent reviewers screened studies for inclusion.</p><p><strong>Assessment of risk of bias: </strong>Risk of bias was assessed using the revised Cochrane RoB 2 tool.</p><p><strong>Data synthesis and analysis: </strong>Treatment effects were estimated with pooled risk ratios (RRs) using random effects meta-analysis. Heterogeneity between studies was assessed with Cochran's Q-statistic and <i>I</i> ² test.</p><p><strong>Results: </strong>Of 437 articles identified, three RCTs met inclusion criteria. Primary outcome of treatment success or cure was not meta-analysed due to clinical heterogeneity. Combination therapy did not significantly improve mortality (RR 0.85; 95% CI, 0.28-2.52; <i>I²</i>  = 27.8%) or persistent bacteraemia (RR 0.34; 95% CI, 0.04-2.59; <i>I²</i>  = 0%). Participants receiving combination therapy had more adverse events leading to treatment discontinuation, but this was not statistically significant (RR 1.84; 95% CI, 0.36-9.36; <i>I²</i>  = 18%).</p><p><strong>Conclusions: </strong>In this meta-analysis of three RCTs, fosfomycin combination therapy for <i>S. aureus</i> bacteraemia or endocarditis did not significantly improve patient outcomes and may be associated with higher rates of adverse events.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf101"},"PeriodicalIF":3.7,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Incidence, characteristics and risk factors of tigecycline-induced hypoglycaemia: a retrospective study from the real world.","authors":"","doi":"10.1093/jacamr/dlaf111","DOIUrl":"https://doi.org/10.1093/jacamr/dlaf111","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/jacamr/dlaf076.].</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf111"},"PeriodicalIF":3.7,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12168117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring variability in antibiograms: a cross-sectional study.","authors":"Valerie Leung, Marwah Alameri, Huda Almohri, Kevin A Brown, Nick Daneman, Julianne V Kus, Larissa M Matukas, Kevin L Schwartz, Bradley J Langford","doi":"10.1093/jacamr/dlaf084","DOIUrl":"10.1093/jacamr/dlaf084","url":null,"abstract":"<p><strong>Background: </strong>Antibiograms are important tools for guiding empirical antimicrobial prescribing and monitoring antimicrobial resistance (AMR); however, there are challenges to their implementation and interpretation in practice. Variable formatting may be a contributing factor. This study explores variability in antibiogram data presentation to identify opportunities for improvement.</p><p><strong>Methods: </strong>Antibiograms from hospitals in Ontario were evaluated by visual inspection for general formatting and style, organism-specific data presentation and stratification based on CLSI M39 guidelines (Fifth Edition, 2022) and relevant literature. Hospitals were categorized by type and descriptive analysis was performed.</p><p><strong>Results: </strong>Forty-three antibiograms from 60 hospitals were included: 33.3% were large community; 26.7% were academic teaching; 20% were small community; 11.7% were medium community; and 8.5% were complex continuing care/rehabilitation facilities. All antibiograms reported at least 1 year of data, with 26.5% aggregating data from multiple facilities. Most either reported on organisms with at least 30 isolates (23.2%) or included a statement about interpretation of small numbers (69.8%). Only 27.9% included a statement about exclusion of duplicates, and 18.6% included guidance on how to use the antibiogram. Data were reported separately for <i>Staphylococcus aureus</i>, MRSA and MSSA in 39.5% of antibiograms. Almost half of antibiograms incorporated at least one method of stratification; specimen source was most common (39.5%); and 18.6% (<i>n</i> = 8) included a weighted-incidence syndromic combination antibiogram (WISCA).</p><p><strong>Conclusions: </strong>There is significant variability in antibiogram data presentation across Ontario hospitals. Additional format standardization may help improve use for clinical decision-making and monitoring of AMR trends.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf084"},"PeriodicalIF":3.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: AMRrounds: presumed mechanisms of resistance in a case of XDR <i>Klebsiella pneumoniae</i> empyema.","authors":"","doi":"10.1093/jacamr/dlaf104","DOIUrl":"https://doi.org/10.1093/jacamr/dlaf104","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/jacamr/dlaf019.].</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf104"},"PeriodicalIF":3.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12160008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}